OptiBiotix Health PLC Extension of term and territories for LPLDL® (9309S)
15 March 2019 - 6:00PM
UK Regulatory
TIDMOPTI
RNS Number : 9309S
OptiBiotix Health PLC
15 March 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Extension of term and territories for LP(LDL) (R) capsules with
HLH Biopharma GmbH
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its fully-owned subsidiary ProBiotix
Health Ltd., has extended its original supply agreement (see RNS:
15 June 2017) with HLH BioPharma Vertriebs GmbH ("HLH") covering
the supply of LP(LDL) (R) capsules. The new agreement grants HLH:
-
-- An exclusive license to produce, package and commercialise a
customised capsular product containing OptiBiotix's cholesterol
reducing LP(LDL) (R) strain in Germany with order volume
commitments which double each year for the next three years to
maintain exclusivity in this territory
-- A nonexclusive license to produce, package and commercialise
products containing OptiBiotix's cholesterol reducing LP(LDL) (R)
strain in Austria, Switzerland and the United Arab Emirates
(UAE)
-- The agreement is for three years from the data of signing
-- The agreement restricts HLH from promoting and/or making
sales, or exporting products outside these territories
HLH have over 20 years' experience in the distribution of
probiotic and natural products under the brand names Lactobact(R)
and is one of Europe's leading suppliers of probiotics to the
pharmacy market.
This agreement recognises the successful launch of HLH in
capsules containing LP(LDL) (R) (RNS: 26 July 2017) under the brand
name Lactobact(R) LDL-Control and promoting them directly to the
pharmacy market in Germany and to consumers on their online
platform. The commitment to double order volumes each year for the
next three years to maintain exclusivity reflects the growing
confidence from HLH in the science and effectiveness of LP(LDL)
(R). This is another important step, in this case with an existing
partner, in OptiBiotix's strategy of building the LP(LDL) (R)
brand, to serve multiple consumer healthcare and pharmaceutical
markets around the world.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce this extension of terms and territory with HLH who are one
of Europe's leading suppliers of probiotics to the pharmacy market.
The agreement recognises the success of HLH in building sales of
its LP(LDL) (R) containing Lactobact(R) brand in Germany and
extends the terms and territory to support further sale growth.
This is another step in extending the geographical reach of LP(LDL)
(R) as it builds recurring revenue streams and increases brand
recognition, and the value of its products. This is part of a
strategy which allows OptiBiotix to present customised product
solutions through its partners to consumer health, pharmaceutical
and retail companies around the world."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance) Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRUSAVRKUAOAAR
(END) Dow Jones Newswires
March 15, 2019 03:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024